Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BioNTech SE - American Depositary Shares (NQ:BNTX)

95.81 -2.85 (-2.89%)
Streaming Delayed Price Updated: 11:31 AM EDT, Sep 18, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about BioNTech SE - American Depositary Shares

< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
73 74 Next >
News headline image
Moderna And BioNTech Bet On Personalized Cancer Vaccines To Revive Fortunes After Dwindling COVID-19 Vaccine Sales ↗
BioNTech and Moderna are advancing personalized cancer vaccines using mRNA technology. Despite promising early results, these innovative treatments face challenges in cost, scalability, and... 
Via Benzinga
News headline image
Americans To Access COVID-19 Test Kits For Free As US Government Restarts Free At-Home Program ↗
US households can order free COVID-19 tests starting in late September as the government reopens the program ahead of the fall virus season. 
Via Benzinga
News headline image
FDA Approves Updated COVID Vaccines From Pfizer And Moderna, But Leaves Out Novavax's Shot ↗
The FDA granted emergency use authorization for updated mRNA COVID-19 vaccines targeting the Omicron KP.2 strain, including new formulas from Moderna and Pfizer/BioNTech. These vaccines, designed to... 
Via Benzinga
News headline image
Pfizer and BioNTech Receive U.S. FDA Approval & Authorization for Omicron KP.2-adapted COVID-19 Vaccine
From Pfizer Inc.
Via Business Wire
News headline image
Unveiling 12 Analyst Insights On BioNTech ↗
 
Via Benzinga
News headline image
Navigating 12 Analyst Ratings For BioNTech ↗
 
Via Benzinga
News headline image
Pfizer and BioNTech Receive U.S. FDA Approval & Authorization for Omicron KP.2-adapted COVID-19 Vaccine
From BioNTech SE
Via GlobeNewswire
News headline image
FDA Set To Approve COVID-19 Vaccines As Soon As This Week: Stocks, ETFs To Watch ↗
The FDA may approve updated COVID-19 vaccines this week to combat recent strains as the country endures a significant summer outbreak. 
Via Benzinga
Topics ETFs
News headline image
Moderna Dips on Q2 Earnings But Can It Rip on a Short Squeeze?
Biotechnology company Moderna Inc. (NASDAQ: MRNA) stock rocked investors with a 30% drop following its second-quarter 2024 earnings release. 
Via MarketBeat
News headline image
FDA Allows Resumption Of BioNTech/MediLink Therapeutics Partnered Phase 1 Study For Cancer Drug With Lower Dose ↗
FDA lifts partial hold on MediLink Therapeutics' phase 1 trial for HER3-targeting ADC BNT326/YL202 in advanced lung and breast cancer patients; trial resumes with revised dose limits following safety... 
Via Benzinga
News headline image
Pfizer and BioNTech's Combo Shot Missed the Mark. Is It Time to Sell? ↗
A clinical-trial failure for Pfizer and BioNTech means Moderna is leading the race to develop a combo shot for the flu and COVID-19. 
Via The Motley Fool
News headline image
Why Pfizer Stock Slumped on Friday ↗
Investors were cautiously pessimistic about the latest news coming out of the company's lab. 
Via The Motley Fool
News headline image
Pfizer Slides Toward Sell Zone After BioNTech-Tied Covid/Flu Shot Misses Its Mark ↗
The company is now considering whether it needs to change up the vaccine to pass muster. 
Via Investor's Business Daily
News headline image
Pfizer, BioNTech's COVID-19/Flu Combo Vaccine Fails To Meet Key Goal In Late-Stage Study ↗
Pfizer and BioNTech report Phase 3 results for their combined mRNA vaccine against influenza and COVID-19. The trial met one of two primary immunogenicity objectives. Adjustments are planned to improve... 
Via Benzinga
News headline image
Pfizer and BioNTech Provide Update on mRNA-based Combination Vaccine Program Against Influenza and COVID-19 in Individuals 18-64 Years of Age
From Pfizer Inc.
Via Business Wire
News headline image
Pfizer and BioNTech Provide Update on mRNA-based Combination Vaccine Program Against Influenza and COVID-19 in Individuals 18-64 Years of Age
From BioNTech SE
Via GlobeNewswire
News headline image
Struggling COVID-19 Vaccines From AstraZeneca, BioNTech/Pfizer, Moderna Cut Incidence Of Arterial Thromboses That Cause Heart Attacks, Strokes, British Study Shows ↗
COVID-19 vaccinations could lower the incidence of heart attacks and strokes, according to a new study by UK universities. The research shows a significant reduction in cardiovascular events among... 
Via Benzinga
News headline image
Long Covid Remains Diagnostic Mystery, Diagnosis Remains Elusive; National Institutes of Health-Funded Study Shows ↗
A recent NIH study reveals no clear diagnostic test for Long Covid, highlighting ongoing challenges in identifying and treating the condition affecting millions of Americans. Researchers continue to... 
Via Benzinga
News headline image
Novavax Plunges on Earnings Miss: Falling Knife or Buying Opp?
Novavax Inc. (NASDAQ: NVAX) is a biotechnology company that focuses on developing and commercializing vaccines for serious infectious diseases. 
Via MarketBeat
News headline image
3 Biotech Stocks With Promising Drug Pipelines: August 2024 ↗
The biotech stocks with promising pipelines could see shares soar if drugs in late-stage trials get FDA approval. 
Via InvestorPlace
News headline image
This Cognizant Technology Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Wednesday ↗
 
Via Benzinga
News headline image
BioNTech Se (BNTX) Q2 2024 Earnings Call Transcript ↗
BNTX earnings call for the period ending June 30, 2024. 
Via The Motley Fool
Topics Earnings
News headline image
US Stocks Trim Black Monday's Drops As Services Gauge Expands, Bond Gains Stall As Traders Reassess Fed Cuts: What's Driving Markets Monday? ↗
Global markets are experiencing intense volatility, and while it seemed like a Black Monday for Wall Street was inevitable following a 13% overnight tumble of Japan’s Nikkei 225, stock indices are... 
Via Benzinga
Topics Economy
News headline image
Moderna Lost 27% Of Its Value Over Two Days. It Just Crumbled Again. ↗
Moderna sustained a rare downgrade on Monday following its guidance cut for the year. 
Via Investor's Business Daily
News headline image
BNTX Stock Earnings: BioNTech Misses EPS, Misses Revenue for Q2 2024 ↗
BNTX stock results show that BioNTech missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
BioNTech's Q2 Loss Widens Amid Low Demand For Its Pfizer-Partnered COVID-19 Vaccine, Increases R&D Spending On New Cancer Products ↗
BioNTech posted a significant Q2 2024 loss of 807.8 million euros. Sales dropped to 128.7 million euros as the demand for COVID-19 vaccines shifted. R&D expenses rose due to late-stage oncology... 
Via Benzinga
News headline image
Nasdaq, R2K Futures Tumble Over 4%, VIX Spikes Over 100%, Bitcoin Plunges Hard As Global Sell-Off Deepens Amid Recession Fears ↗
The stock market is on track to gap-open sharply lower on Monday as negative sentiment seen in the final two sessions of last week has carried over into the new week. The index futures were all sharply... 
Via Benzinga
Topics Economy Stocks
News headline image
BioNTech Announces Second Quarter 2024 Financial Results and Corporate Update
From BioNTech SE
Via GlobeNewswire
News headline image
What's Going On With BioNTech (BNTX) Shares? ↗
BioNTech shares are trading lower by 5.3% during Thursday's session. Vaccine stocks are down after Moderna cut its 2024 outlook due to weak EU sales and increased U.S. competition. 
Via Benzinga
News headline image
Moderna Slashes Its Outlook On 'Very Low' European Sales Despite Quarterly Beat ↗
Moderna delivered nearly double the sales analysts expected in the second quarter. 
Via Investor's Business Daily
< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
73 74 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.